Cilostazol prevents progression of asymptomatic carotid artery stenosis in patients with contralateral carotid artery stenting

American Journal of Neuroradiology

Volumn 33, Issue 7, 2012, Pages 1262-1266

  Kato, Takayuki ^a   Sakai, H ^a   Takagi, T ^a   Nishimura, Y ^a  

^a Department of Oral and Maxillofacial Surgery   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; TICLOPIDINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CAROTID ARTERY STENTING; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE COURSE; ECHOGRAPHY; FEMALE; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTOR VARIABLE;

AGED; AGED, 80 AND OVER; BLOOD VESSEL PROSTHESIS; CAROTID STENOSIS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS; STENTS; TETRAZOLES; TREATMENT OUTCOME;

EID: 84865307381     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2955     Document Type: Article

References (56)

1. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991;325:445-53
2. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995;273:1421-28
3. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379-87
4. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004;363:1491-502
5. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 2004;351:1493-501
6. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006;355:1660-71
7. Ringleb PA, Allenberg J, Bruckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006;368:1239-47
8. Ederle J, Dobson J, Featherstone RL, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010;375:985-97
9. Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;363:11-23
10. AbuRahma AF, Cook CC, Metz MJ, et al. Natural history of carotid artery stenosis contralateral to endarterectomy: results from two randomized prospective trials. J Vasc Surg 2003;38:1154-61
11. Raman KG, Layne S, Makaroun MS, et al. Disease progression in contralateral carotid artery is common after endarterectomy. J Vasc Surg 2004;39:52-57
12. Ballotta E, Da Giau G, Meneghetti G, et al. Progression of atherosclerosis in asymptomatic carotid arteries after contralateral endarterectomy: a 10-year prospective study. J Vasc Surg 2007;45:516-22
13. Fluri F, Engelter ST, Wasner M, et al. The probability of restenosis, contralateral disease progression, and late neurologic events following carotid endarterectomy: a long-term follow-up study. Cerebrovasc Dis 2008;26:654-58
14. Chaturvedi S, Yadav JS. The role of antiplatelet therapy in carotid stenting for ischemic stroke prevention. Stroke 2006;37:1572-77
15. Iida O, Nanto S, Uematsu M, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008;48:144-49
16. Ishii H, Kumada Y, Toriyama T, et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol 2008;3:1034-40
17. Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009;53:48-53
18. Soga Y, Iida O, Hirano K, et al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 2010;52:608-15
19. Suzuki K, Iida O, Soga Y, et al. Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry. Circ J 2011;75:939-44
20. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-32
21. Ahn Y, Jeong MH, Jeong JW, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients-clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008;72:35-39
22. Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008;155:1081-89
23. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-87
24. Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol 2010;50:415-21
25. Dihu JB, Abudayyeh I, Saudye HA, et al. Cilostazol: a potential therapeutic option to prevent in-stent restenosis. J Am Coll Cardiol 2011;57:2035-36
26. Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011;57:1264-70
27. Takigawa T, Matsumaru Y, Hayakawa M, et al. Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010;51:51-56
28. Yamagami H, Sakai N, Matsumaru Y, et al. Periprocedural cilostazol treatment and restenosis after carotid artery stenting: The Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS). J Stroke Cerebrovasc Dis 2012;21:193-99
29. Yoshimoto T, Fujimoto S, Muraki M, et al. Cilostazol may suppress restenosis and new contralateral carotid artery stenosis after carotid endarterectomy. Neurol Med Chir (Tokyo) 2010;50:525-29
30. Kato T, Sakai H, Tsujimoto M, et al. Prolonged carotid sinus reflex is a risk factor for contrast-induced nephropathy following carotid artery stenting. AJNR Am J Neuroradiol 2011;32:441-45
31. Jahromi AS, Cina CS, Liu Y, et al. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. J Vasc Surg 2005;41:962-72
32. Rockman CB, Riles TS, Lamparello PJ, et al. Natural history and management of the asymptomatic, moderately stenotic internal carotid artery. J Vasc Surg 1997;25:423-31
33. Olin JW, Fonseca C, Childs MB, et al. The natural history of asymptomatic moderate internal carotid artery stenosis by duplex ultrasound. Vasc Med 1998;3:101-08
34. Mansour MA, Littooy FN, Watson WC, et al. Outcome of moderate carotid artery stenosis in patients who are asymptomatic. J Vasc Surg 1999;29:217-25
35. Muluk SC, Muluk VS, Sugimoto H, et al. Progression of asymptomatic carotid stenosis: a natural history study in 1004 patients. J Vasc Surg 1999;29:208-14
36. Liapis C, Kakisis J, Papavassiliou V, et al. Internal carotid artery stenosis: rate of progression. Eur J Vasc Endovasc Surg 2000;19:111-17
37. Cinà CS, Safar HA, Maggisano R, et al. Prevalence and progression of internal carotid artery stenosis in patients with peripheral arterial occlusive disease. J Vasc Surg 2002;36:75-82
38. Jahromi AS, Clase CM, Maggisano R, et al. Progression of internal carotid artery stenosis in patients with peripheral arterial occlusive disease. J Vasc Surg 2009;50:292-98
39. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74
40. de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data metaanalysis. Stroke 2010;41:1294-97
41. Qureshi AI, Janardhan V, Bennett SE, et al.Whoshould be screened for asymptomatic carotid artery stenosis? Experience from the Western New York Stroke Screening Program. J Neuroimaging 2001;11:105-11
42. Marek J, Mills JL, Harvich J, et al. Utility of routine carotid duplex screening in patients who have claudication. J Vasc Surg 1996;24:572-77; discussion 577-79
43. Fine-Edelstein JS, Wolf PA, O'Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994;44:1046-50
44. O'Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992;23:1752-60
45. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-57
46. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-89
47. Nicolaides AN, Kakkos SK, Griffin M, et al. Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Eur J Vasc Endovasc Surg 2005;30:275-84
48. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009;40:e573-83
49. Han Y, Wang S, Li Y, et al. Cilostazol improves long-term outcomes after coronary stent implantation. Am Heart J 2005;150:568
50. Lee SW, Chun KJ, Park SW, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 2010;105:168-73
51. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782-86
52. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959-68
53. Ikeda Y, Kikuchi M, Murakami H, et al. Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Drug Research 1987;37:563-66
54. Tanaka T, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988;36:313-20
55. Tanaka K, Gotoh F, Fukuuchi Y, et al. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989;20:668-73
56. Ishiguro M, Mishiro K, Fujiwara Y, et al. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010;5:e15178